Evidence map›Paper›PMID 25851105›Full record

ArticleJournal of molecular modeling2015

On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.

Jacek Kujawski, Marek K Bernard, Elżbieta Jodłowska, Kornelia Czaja, Beata Drabińska

Abstract read
In one paragraph

Article in Journal of molecular modeling, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jacek KujawskiDepartment of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, Grunwaldzka 6 street, 60-780, Poznań, Poland, jacekkuj@ump.edu.pl.
Marek K Bernard
Elżbieta Jodłowska
Kornelia Czaja
Beata Drabińska

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leflunomide is a disease-modifying antirheumatic drug with antiinflammatory and immunosuppressive activity used for the treatment of psoriatic and rheumatoid arthritis. It undergoes rapid metabolization to teriflunomide, a metabolite that is responsible for the biological activity of leflunomide. Continuing our investigations on the interactions of biologically important azahetarenes with the environment, we focused on leflunomide and its active metabolite, teriflunomide, considering the interactions teriflunomide-amino acid within the target protein (dihydroorotate dehydrogenase) using density functional theory, as well as ONIOM techniques. The results of theoretical studies have shown that the interactions of teriflunomide with tyrosine and arginine involve principally the amide fragment of teriflunomide. The presence of the internal hydrogen bond between (Z)-teriflunomide carbonyl oxygen and enolic hydroxyl decreases the interaction strength between teriflunomide and tyrosine or arginine. Even the E isomer of teriflunomide would usually provide a stronger interaction teriflunomide-amino acid than the Z isomer with the internal hydrogen bond.

Indexed as

Models, MolecularAntirheumatic AgentsArthritis, RheumatoidBinding SitesCrotonatesDihydroorotate DehydrogenaseEnergy MetabolismHumansHydrogen BondingHydroxybutyratesIsoxazolesLeflunomideMagnetic Resonance SpectroscopyNitrilesOxidoreductases Acting on CH-CH Group DonorsToluidinesAntirheumatic AgentsCrotonatesDihydroorotate DehydrogenaseHydroxybutyratesIsoxazolesLeflunomideNitrilesOxidoreductases Acting on CH-CH Group DonorsteriflunomideToluidines

Identifiers

PMID25851105
PMCPMC4391734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.